Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Grifols International

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hyperimmune globulin

            Therapeutic Area: Infections and Infectious Diseases Product Name: ITAC

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            Details:

            First international multicenter clinical trial of an anti-SARS-CoV-2 hyperimmune globulin and will include 500 hospitalized adults with COVID-19 in up to 58 hospitals in 18 countries. The therapy comes from the convalescent plasma of healthy people who have recovered COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Plasma-based therapies

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Recipient: Alkahest

            Deal Size: $146.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 07, 2020

            Details:

            Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Perflutren,Immunoglobulin G 285-292

            Therapeutic Area: Neurology Product Name: Albutein

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            Details:

            Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fostamatinib Disodium

            Therapeutic Area: Hematology Product Name: Tavalisse

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Rigel Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2020

            Details:

            TAVLESSE, which is marketed in the U.S. under the brand name TAVALISSE®, is an oral spleen tyrosine kinase (SYK) inhibitor that targets the underlying autoimmune cause of ITP by impeding platelet destruction.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-SARS-CoV-2 hyperimmune globulin therapy

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            Details:

            The company has started production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the first specific drug developed to combat COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ciprofloxacin

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Savara

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 02, 2020

            Details:

            Under the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Immune globulin human-klhw

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Soleo Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 01, 2020

            Details:

            Soleo Health was chosen as a limited distributor of XEMBIFY. This is Grifols’ first 20% immune globulin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-SARS-CoV-2 hyperimmune globulin therapy

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 25, 2020

            Details:

            Grifols will volunteer its expertise and resources in the areas of plasma collection using its network of plasma donor centers; test and qualify donors in conjunction with other health agencies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ciprofloxacin

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Recipient: Aradigm

            Deal Size: $6.2 million Upfront Cash: $3.2 million

            Deal Type: Acquisition February 21, 2020

            Details:

            Grifols, S.A.will acquire the Company’s assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof.